Northern Trust Corp Sells 22,759 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Northern Trust Corp reduced its stock position in IQVIA Holdings Inc. by 1.3%, owning approximately 1.02% of the company worth $311.78 million after selling 22,759 shares.
• Competing firms have increased their stakes in IQVIA, with JPMorgan Chase & Co. leading the charge with a 45.7% increase, now holding $448.69 million in shares.
• IQVIA reported quarterly earnings of $2.81 EPS, surpassing estimates of $2.77, with a 5.3% year-over-year revenue increase to $4.02 billion.

Northern Trust Corp reduced its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,768,470 shares of the medical research company's stock after selling 22,759 shares during the period. Northern Trust Corp owned approximately 1.02% of IQVIA worth $311,781,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sowell Financial Services LLC bought a new stake in IQVIA in the 1st quarter valued at $305,000. Mather Group LLC. increased its holdings in IQVIA by 83.5% in the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after acquiring an additional 350 shares during the last quarter. Private Advisor Group LLC increased its holdings in IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock valued at $958,000 after acquiring an additional 566 shares during the last quarter. Park Avenue Securities LLC increased its holdings in shares of IQVIA by 40.4% in the 1st quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock worth $956,000 after buying an additional 1,562 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of IQVIA by 34.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock worth $2,338,000 after buying an additional 3,398 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Up 3.0%

NYSE:IQV traded up $5.5970 during mid-day trading on Friday, hitting $190.9870. 1,619,418 shares of the stock traded hands, compared to its average volume of 1,441,272. The stock has a market capitalization of $32.47 billion, a price-to-earnings ratio of 27.64, a PEG ratio of 2.10 and a beta of 1.30. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The firm's 50 day moving average is $173.70 and its two-hundred day moving average is $168.26. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on IQV shares. Truist Financial boosted their target price on shares of IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Robert W. Baird boosted their target price on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Barclays boosted their target price on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Redburn Partners set a $188.00 target price on shares of IQVIA in a report on Friday, May 23rd. Finally, Cowen restated a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.

Insider Transactions at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.